Akari Therapeutics Plc

Akari Therapeutics is a biopharmaceutical company whose core business involves animal testing as part of its drug development process. The company’s lead clinical-stage programs, including those for complement-mediated diseases, rely on preclinical research that necessitates the use of animals to assess safety and efficacy. This places the company within the broad category of commercial animal exploitation, as its research and development model is fundamentally dependent on animal experimentation.

While specific details regarding the scale, species, or protocols of Akari’s animal testing are not publicly disclosed in the gathered evidence, the company’s operational focus on novel therapeutic candidates confirms that animal testing is an integral and ongoing component of its business. The absence of a publicly available animal welfare policy or a commitment to alternative testing methods further underscores its reliance on conventional animal models.